Biomarkers for immune thrombocytopenia

Lingjia Yu, Chunmei Zhang†, Liping Zhang †, Yongyu Shi and Xuebin Ji*

Abstract

Immune thrombocytopenia is an autoimmune disease with abnormal biomarkers. Immune thrombocytopenia pathogenesis is a complicated process in which the patient’s immune system is activated by platelet autoantigens resulting in immune mediated platelet destruction or suppression of platelet production. The autoantibodies produced by autoreactive B cells against self antigens are considered to play a crucial role. In addition, biomarkers such as transforming growth factor-beta1, Toll-like receptors, T helper 1 and T helper 2 cytokine bias, Notch signaling and abnormal biomarker in megakaryocyte maturation are involved in the pathogenesis of this disease. With the genomewide association study on immune thrombocytopenia, more biomarkers will be founded in the future. They may provides a theoretical basis for the mechanism and treatment of immune thrombocytopenia.

Keywords: Immune thrombocytopenia, Biomarker, T cell, B cell, Pathogenesis

Introduction

Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder in which the patient’s immune system is activated by platelet autoantigens resulting in immune-mediated platelet destruction and/or suppression of platelet production with the clinical manifestations of oral gingival and skin mucous membrane bleeding.

Biomarkers are very important to the pathogenesis of disease. Many abnormal immune biomarkers play crucial roles in ITP pathogenesis [1]. The abnormal B, T cell and some new biomarkers in ITP were introduced. It may help people to know the complicated pathogenesis of ITP.

Abnormal B cell immune biomarkers

ITP is an autoimmune disease. Glycoprotein (GP) specific autoantibodies (e.g., GPVI, GPIb/IX, GPIIb/IIIa autoantibodies) can be detected in most ITP patients’ plasma or platelet eluates by modified monoclonal antibody immobilization of platelet antigen (MAIPA) assay, which bind to the specific glycoproteins by an antigen-binding fragment (Fab) and then activate the mononuclear-macrophage or complement system [2, 3]. The autoantibodies produced by autoreactive B cells against self-antigens, specifically immunoglobulin G (IgG) antibodies against GPIIb/IIIa and/or GPIb/IX, are considered to play a crucial role in the platelet destruction [4].

Approximately 75 % of platelet autoantigens are localized to either the platelet GP IIB/IIIa or GP Ib/IX complex. Inhibition of the binding of autoantibodies from several ITP patients by either another ITP autoantibody or by a monoclonal anti-GPIIb/IIIa antibody suggests that the antigenic repertoire in chronic ITP may be limited. Many patients may produce multiple antibodies. Once produced, antiplate autoantibodies may either bind to platelets, causing their destruction by either phagocytosis or possibly complement activation and lysis, or bind to megakaryocytes, resulting in decreased thrombopoiesis. A variety of new investigative techniques including MAIPA assay have localized a few autoantigens to specific regions of the cytoplasmic or extracellular regions of both GPIIb/IIIa and GPIb/IX. These methods that allow incubation of patient serum or plasma with intact platelets (MAIPA and immunobead) have greater sensitivity than techniques in which the patient antibody is tested against previously isolated platelet glycoproteins [5].

Platelets with affiliated IgG are targeted for exploitation by Fc receptor-mediated phagocytic cellular material within the reticuloendothelial system. The expression of FC gamma receptors (FCGR) IIB was decreased in ITP. Lower expression of FCGRIIb may be involved in the pathogenesis of ITP. An increasing in FCGRIIb may be considered as a therapeutic target for human ITP treatment or possibly as a new biomarker for ITP analysis [6].
It was demonstrated decreased expression of FCGRIIb and elevated expression of FCGRIIa and FCGRIII on monocytes in ITP patients before high-dose dexamethasone (HDDXM) therapy. HD-DXM treatment may change the FCGR balance toward the inhibitory FCGRIIb, thus providing new insights into the mechanism of HD-DXM in the treatment of ITP [7].

B-cell activating factor (BAFF; also known as B-lymphocyte stimulator) belonging to the family of tumor necrosis factor (TNF) ligands is critical for the maintenance of normal B-cell development, homeostasis, and autoreactivity [8, 9] and T-cell costimulation [10–12]. BAFF is an important homeostatic cytokine for B cells that is up-regulated during inflammation and links adaptive with innate immunity. BAFF has been shown to enhance the expression of CD19 and mediate the maturation of autoreactive B cells. It is shown that BAFF is elevated in ITP patients with active disease, and excessive BAFF may rescue autoreactive B and T cells from apoptosis [13].

Abnormal T cell immune biomarkers

The cytokine transforming growth factor-beta1 (TGF-β1) is a central player in maintaining the immune response balance, which belongs to regulator T cell (Treg) cytokines. Tregs play crucial roles in the induction and maintenance of immune tolerance, which are involved in ITP abnormal T cell immunity. It was found that the concentration TGF-β1 was lower in ITP patients [14]. The dominant function of TGF-β1 is to regulate peripheral immune homeostasis [15].

Toll-like receptors (TLRs) are the major molecules involved in the immune regulatory process [16, 17]. TLRs play an important role in defending the host against pathogenic microbes through the induction of inflammatory cytokines and type I interferons. Furthermore, TLRs play roles in shaping pathogen-specific humoral and cellular adaptive immune responses [18]. TLRs have been found to be associated with immune-mediated diseases but it is still not clear whether they play a role in ITP, especially TLR4. CD4+ T-lymphocyte abnormalities, including T helper (Th)17. Th1, Th2, and Treg are considered important in ITP. It was showed that TLR4, CD4+ T cells (Th1, Th17 and Treg cells) and related cytokines may take part in the pathogenesis of ITP. TLR4 may play a role through the TLR4-cytokine-CD4+ T lymphocyte cell pathway [19].

Th1 polarization persists in the autoimmune response found in ITP. TLR7 expression, which also plays an important role in autoimmune diseases, was found increasing in ITP. The findings indicate that TLR7 promotes Th1 polarization and may contribute in ITP pathogenesis [20].

Th1/Th2 cytokine bias may be an important mechanism of ITP. The Th1/Th2 balance is important to normal human immunity. Th1 cells primarily secrete the inflammatory cytokines interleukin (IL)-2, IL-12, interferon-gamma (IFN-γ) and TNF-β. Th2 cells primarily secrete the inflammatory cytokines IL-4, IL-5, IL-6 and IL-10.

ITP is associated with a Th1 type of T helper cytokine response, while that of type Th2 is downregulated. The present study demonstrates that an imbalance of Th1 and Treg cytokines may mediate the pathogenesis of ITP [21]. Uncontrolled Th-1 lymphocyte activation may be an important mechanism of ITP. Treatment with a large dose of dexamethasone, the Th1-type cytokine spectrum returns to the dominant position after treatment with dexamethasone [22]. Shifting the cytokine patterns from Th1 to Th2 may be a potential immunotherapy for ITP.

Cytotoxic T-lymphocytes (CTLs) can induce the lysis of autologous platelets. CTLs-mediated platelet destruction and aberrant cytokine profiles play important roles in the pathogenesis of ITP. Interleukin-27 (IL-27) has pleiotropic immunomodulatory effects. The results suggest that IL-27 can inhibit CTL-mediated platelet destruction by negatively regulating CTL cytoxicity toward platelets in ITP. IL-27 may have a therapeutic role in treating ITP patients [23].

Notch signaling has been implicated in peripheral T-cell activation and effector cell differentiation. Th17 cells and Treg cells, along with Th1 and Th2 cells, may contribute to the pathogenesis of ITP. The imbalance of Th17/Treg toward Th17 cells has been shown to play an important role in the peripheral immune response. However, the role of Th17/Treg in the pathogenesis of ITP and the effect of Notch signaling on Th17/Treg imbalances still remain uncertain in ITP [24].

To investigate the role of Notch signaling pathway in ITP, the expression of Notch pathway molecules in ITP patients were measured and evaluated their clinical relevance. It was found that Notch1 and Notch3 expression elevated, while Notch2 decreased statistically in ITP patients. The findings suggest that the Notch signaling pathway may be involved in ITP. The blockage of Notch1 pathway may be a promising therapeutic method [25].

Abnormal biomarker in ITP megakaryocyte maturation

Tumor necrosis factor-related megakaryocyte maturation (TRAIL) belongs to the TNF super-family protein biomarkers. TRAIL can promote the apoptosis and maturation of megakaryocytes. It was demonstrated that low expression of TRAIL in megakaryocytes contributed to impaired platelet production in ITP. TRAIL expression on megakaryocytes and the TRAIL concentrations of ITP patients were decreased. Megakaryocyte apoptosis mediated by TRAIL in the plasma of ITP patients may be a potential mechanism by which the megakaryocyte number increases in vitro [26]. It was found that low dose decitabine can promote megakaryocyte maturation
and platelet production and enhance TRAIL expression in megakaryocytes in healthy controls and ITP [27].

New biomarkers in ITP

Genetic sequence variations, such as single nucleotide polymorphisms (SNPs), may have biological roles in modifying the outcome risk of many diseases. Genomewide association study(GWAS) is a new method that can be used to find genetic characteristic SNPs of many complex disease by case–control association analysis [28, 29]. GWAS on ITP may find some genetic SNPs which can be developed to new biomarkers for the clinical practice, individualized diagnosis and treatment of ITP.

Conclusions

ITP is an autoimmune disease with abnormal immune biomarkers. The autoantibodies produced by autoreactive B cells against self-antigens, specifically antibodies against GPIb/IIa and/or GPIb/IX, are considered to play a crucial role in the pathogenesis of ITP. Biomarkers such as TGF-β1,TLRs, Notch signaling, TRAIL,Th1/Th2 cytokine bias are involved in ITP T cell abnormality. With the GWAS on ITP, more biomarkers will be founded in the future. They may provides a theoretical basis for the mechanism and treatment of ITP.

Abbreviations

ITP: immune thrombocytopenia; MAIPA: modified monoclonal antibody immobilization of platelet antigen; Treg: T regulatory cell; FCGR: FC gamma receptors; Th: T helper; TLR: toll-like receptors; IFN-γ: interferon-gamma; TGF-β: transforming growth factor-beta; IL: interleukin; TNF-β: tumor necrosis factor-beta; GP: glycoprotein; TRAIL: tumor necrosis factor-related apoptosis-inducing ligand; GWAS: genomewide association study.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

The present manuscript was drafted by LY and CZ, edited by LZ and YS, and revised by XJ. All of the authors read and approved the final version of the manuscript.

Authors’ information

Chunmei Zhang and Liping Zhang considered as equal first author.

Acknowledgements

The present study was partially supported by the National Natural Science Foundation (81100336), the Science and Technology development Plan of Shandong Province (2014GSF118035), the Natural Science Foundation of Shandong Province (ZR2013HQ001), the Fundamental Research Funds of Shandong University (2015JC03,2015QLM507), the Cultivation Fund of the Key Scientific and Technical Innovation Project, the Ministry of Education of China (NO704030), the Taishan Scholar Foundation, and the SRF for ROCS and SEM.

Author details

1Department of Hematology, Qilu Hospital, Shandong University, 107 West Wenhuad rd, Jinan, Shandong 250012, PR China. 2Department of Hematology, the central Hospital of TaiAn, TaiAn, PR China. 3Jinan Stomatological Hospital, Jinan, PR China. 4Institute of Immunology, School of Medicine, Shandong University, Jinan, PR China.

References

1. Ji X, Zhang L, Peng J, Hou M. T cell immune abnormalities in immune thrombocytopenia. J Hematol Oncol. 2014;7:2.
2. Hou M, Stockelberg D, Kutti J, Wadenbvik H. Antibodies against platelet GPIb/IX, GPIb/IIa, and other platelet antigens in chronic idiopathic thrombocytopenic purpura. Eur J Haematol. 1995;55:307–14.
3. Mc MR. Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production. Hematol Oncol Clin North Am. 2009;23:1163–75.
4. McMillan R. Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. Semin Hematol. 2000;37:239–48.
5. Nugent D, McMillan R, Nichol JS, Slichter SJ. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol. 2009;146:859–96.
6. Wu Z, Zhou J, Prison P, Wei X, Liu X, Peng B. Low expression of FCGRIB in macrophages of immune thrombocytopenia-affected individuals. Int J Hematol. 2012;96:589–93.
7. Liu XG, Ma SH, Sun JZ, Ren J, Shi Y, Sun L, et al. High-dose dexamethasone shifts the balance of stimulatory and inhibitory Fcgamma receptors on monocytes in patients with primary immune thrombocytopenia. Blood. 2011;117:2601–9.
8. Schneider P, Mackay F, Steiner V, Hofmann K, Bodmer JL, Holler N, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999;189:1747–56.
9. Moore PA, Belvedere O, Orr A, Piet K, LaFleur DW, Feng P, et al. BLYs member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999;285:260–3.
10. Huard B, Schneider P, Mauri D, Tschopp J, French LE. T cell costimulation by the TNF ligand BAFF. J Immunol. 2001;167:6225–31.
11. He Q, Wang L, Wells AD, Tao R, Han R, Davidson A, et al. BAFF binding to T cell-expressed BAFF-R costimulates T cell proliferation and alloresponses. Eur J Immunol. 2004;34:2750–9.
12. Huard B, Arlettaz L, Ambrose C, Kindler V, Mauri D, Roosnek E, et al. BAFF production by antigen-presenting cells provides T cell co-stimulation. Int Immunol. 2004;16:467–75.
13. Zhu XJ, Shi Y, Peng J, Guo CS, Shan NN, Qin P, et al. The effects of BAFF and BAFF-R-Fc fusion protein in immune thrombocytopenia. Blood. 2009;114:3362–7.
14. Ma L, Liang Y, Fang M, Guan Y, Si Y, Jiang F, et al. The cytokines (IFN-gamma, IL-2, IL-4, IL-10, IL-17) and Treg cytokine (TGF-beta1) levels in adults with immune thrombocytopenia. Pharmazie. 2014;69:694–7.
15. Malhotra N, Kang J. SMAD regulatory networks construct a balanced immune system. Immunology. 2013;139:1–10.
16. Zhu J, He S, Du J, Wang Z, Li W, Chen X, et al. Local administration of a novel Toll-like receptor 7 agonist in combination with doxorubicin induces durable tumouricidal effects in a murine model of T cell lymphoma. J Hematol Oncol. 2015;8:21.
17. Isaza-Correa JM, Liang Z, van den Berg A, Diepstra A, Visser L. Toll-like receptors in the pathogenesis of human B cell malignancies. J Hematol Oncol. 2014;7:57.
18. Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. Biochem Biophys Res Commun. 2009;388:621–5.
19. Liu H, Ouyang X, Li Y, Zeng H, Wang X, Xie S, et al. Involvement of levels of Toll like receptor-4 in monocytes, CD4+ T-lymphocyte subsets, and cytokines in patients with immune thrombocytopenic purpura. Thromb Res. 2013;132:196–201.
20. Yang Q, Wang B, Yu H, Zhu Y, Wang X, Jiang H, et al. TLR7 promotes Th1 polarization in immune thrombocytopenia. Thromb Res. 2011;128:237–42.
21. Andersson J. Cytokines in idiopathic thrombocytopenic purpura (ITP). Thromb Res. 2013;132:196–201.
22. Ma L, Zhu X, Zhao P, Zhao C, Li X, Zhu Y, et al. Profile of Th17 cytokines (IL-17, TGF-beta, IL-6) and Th1 cytokine (IFN-gamma) in patients with immune thrombocytopenic purpura. Ann Hematol. 2008;87:899–904.
23. Zhou H, Qiu JH, Wang T, Yu Y, Liu XN, Li X, et al. Interleukin 27 inhibits cytotoxic T-lymphocyte-mediated platelet destruction in primary immune thrombocytopenia. Blood. 2014;124:3316–9.
24. Yu S, Liu C, Li L, Tian T, Wang M, Hu Y, et al. Inactivation of Notch signaling reverses the Th17/Treg imbalance in cells from patients with immune thrombocytopenia. Lab Invest. 2015;95:157–67.
25. Ma D, Dai J, Zhu X, Yan S, Zhao P, Zhang J, et al. Aberrant expression of Notch signaling molecules in patients with immune thrombocytopenic purpura. Ann Hematol. 2010;89:155–61.
26. Yang L, Wang L, Zhao CH, Zhu XJ, Hou Y, Peng J, et al. Contributions of TRAIL mediated megakaryocyte apoptosis to impaired megakaryocyte and platelet production in immune thrombocytopenia. Blood. 2010;116:4307–16.
27. Zhou H, Hou Y, Liu X, Qiu J, Feng Q, Wang Y, et al. Low-dose decitabine promotes megakaryocyte maturation and platelet production in healthy controls and immune thrombocytopenia. Thromb Haemost. 2015;113:1021–34.
28. Yang TH, Xon M, DeLisi C. Genome-wide association studies. Methods Mol Biol. 2013;939:233–51.
29. Nakabayashi K, Tajima A, Shirasawa S. Genome-wide association studies: recent advances and future directions. Nihon Rinsho. 2009;67:469–76.